Pensioner accidentally pepper sprays entire spa, injuring 13 people
At around 9.50am on Wednesday, the pensioner began rummaging through her handbag in the entrance of the Keidel Thermal Baths in Freiburg, a city in southwest Germany's Black Forest region.
According to local media, she wanted to show the spray to a friend.
Instead, she accidentally activated the spray, releasing the toxic substance throughout the foyer.
The irritant then reportedly spread throughout the building through the ventilation system.
Thirteen visitors to the thermal baths were affected by the incident and complained of eye irritation.
Emergency services, including police and fire personnel, attended the scene and treated the injured.
According to BILD, the pensioner was one of those injured.
The entire pool was evacuated for around 30 minutes for safety reasons, while the entrance area was mechanically ventilated by emergency services, before guests were allowed to return.
The 80-year-old is reportedly being investigated for negligent bodily harm.
In a statement to The Independent, Oliver Heintz, director of Keidel Mineral-Thermalbad, said:'We regret the incident and the inconvenience caused to our guests.
'The situation was handled quickly and professionally by our team and the emergency services.
'We are in close contact with the authorities and will take the necessary steps to support a thorough clarification.'
The Independent has contacted local police for further comment.
Pepper spray is a non-lethal self-defence tool made from oleoresin capsicum (OC), a chemical derived from hot chilli peppers.
It causes a severe burning sensation in the eyes, skin, and respiratory system, leading to temporary blindness, coughing, difficulty breathing and intense pain.
Pepper spray is illegal to buy, sell or carry in the UK and is classed as an offensive weapon.
In Germany, however, pepper spray is legal for use against animals and people 'in self-defence situations' and can be purchased by people as young as 14 years old.
In 2023, an American Airlines flight was forced to land more than 800 miles from its destination after a passenger released pepper spray into the cabin.
The incident was described by one passenger as 'incredibly scary not being able to breathe'.
According to the US Transportation Security Administration, pepper spray is not allowed in carry-on bags.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
2 days ago
- Telegraph
NHS is ‘failing' British FGM victims
The NHS has been accused of 'failing' victims of female genital mutilation (FGM) by not providing the correct care for survivors. Women and girls are forced to leave the UK to have reconstructive surgery abroad due to the lack of treatment available in Britain, The Telegraph has found. Germany has emerged as one of the main destinations for victims of the practice, with many having to crowdfund up to £30,000 to afford the travel and surgery due to NHS failings, survivors say. FGM involves the cutting of the genitals and is often justified by those who advocate for it as a cultural and religious norm. But it is illegal in most countries, including in Africa and Asia, where it is most prevalent. Human rights groups say the practice is a violation of a woman's sexuality and autonomy. The World Health Organisation states FGM has no health benefits for girls and women and can result in severe bleeding, problems urinating and infections. According to the organisation's updated guidelines, countries should provide comprehensive, trauma-informed care for FGM survivors, including access to reconstructive surgery and effective psychosocial support. The UK falls short of that. Only about 10 per cent of the UK's estimated 170,000 FGM survivors, approximately 17,000 women, are eligible for the NHS's sole surgical intervention – deinfibulation. Deinfibulation is the surgical opening of scar tissue formed from FGM. It is limited to treating only those with Type 3 FGM, the most severe form, which consists of the removal of part or all of the external genitalia and the stitching together of the vaginal opening (often called infibulation). This leaves roughly 153,000 women without any surgical option. Numbers are estimated to be even higher, with many cases not recorded in official statistics. Shamsa Araweelo, an FGM survivor living with chronic pain, was forced to raise £30,000 for reconstructive surgery in Germany, where work in the field is among the most pioneering in Europe. She said: 'The NHS failed to provide me with the healthcare I needed. 'No survivor should have to crowdfund their right to a pain-free life. 'Even if I did have a deinfibulation in the UK, it would mean that they would open you up until they can see the urethra, and then they stop. The NHS won't repair any of the damage.' Dr Dan mon O'Dey, a specialist in reconstructive surgery, said he's seen an influx of patients from the UK visit his practice in Heidelberg, Germany. He said: 'Every week, I have contact with new patients from England… every week, two to three more patients coming from England. 'What I hear, especially from patients… is that [FGM surgery] is something that needs to be improved in England.' His clinic offers procedures beyond deinfibulation, including full reconstructive surgery and structured aftercare. He said deinfibulation has benefits for the patient, especially the ability to urinate freely, but 'more care and treatment might be needed to ensure long-term comfort and prevent complications'. Huda Mohamed, an MBE recipient and a lead specialist midwife at the Whittington, said: 'In Germany, they'll have aftercare, they'll have ongoing support.' Ms Mohamed highlighted that the unmet needs of those with Type 1 and Type 2 FGM can still cause chronic infections, painful menstruation and problems in childbirth, despite it being less severe than Type 3. She said: 'Sometimes they damage the nerves… the women complain about not being able even to wear tight clothes… we don't have that specialist thing. We can't do reconstruction.' July is deemed the 'cutting season', a period during school holidays when girls are considered to be at heightened risk of being taken abroad – mostly to East Africa – to undergo female genital mutilation. In 2023, Amina Noor was convicted of assisting a non-UK person to carry out the procedure overseas 17 years ago. It was the first conviction of its kind under the FGM Act of 2003 and followed the only other successful prosecution related to FGM, in 2019, when a Ugandan woman from east London, was jailed for 11 years for cutting a three-year-old girl. Leyla Hussein, an activist and a survivor, said: 'Because of the convictions they are now taking girls younger and younger. They know now they have to be more careful.' According to research published in February by the University of Birmingham, a girl dies every 12 minutes as a result of FGM-related complications. Ms Hussein said the UK's limited surgical provision for FGM survivors was woefully inadequate. She said: 'Just deinfibulation is not enough… I can give as much therapeutic support as I can but reconstructive surgery would be life-changing for these women. 'The NHS has a duty of care to these women. These are British women. These are women who are suffering, and it's literally a basic duty of care.' The UK's last campaign to raise awareness of FGM was in 2018 and ended in January 2023, according to the Equality and Human Rights Commission. The Government hosts resources on FGM, but does not specify that it is a form of child abuse and violence against women and girls. An NHS spokesman said: 'The NHS is committed to supporting FGM survivors, which is why it has rolled out more than 20 national FGM support clinics across England, where patients can receive a range of support, including referral to a specialist consultant where needed. 'All NHS healthcare professionals have responsibilities to safeguard women and girls at risk of FGM or other abuse, and FGM is part of mandatory safeguarding training for staff.' Juliet Albert, a NHS midwife and advocate for FGM reconstructive surgery, said, 'We are failing FGM survivors. 'It's embarrassing that the UK has not taken this forward for all these years. I mean, in France, since 1998 more than 7,000 women have had reconstruction surgery, and yet we don't even offer it here.'
Reuters
2 days ago
- Reuters
US FDA investigates third death after treatment with Sarepta's gene therapy Elevidys
July 25 (Reuters) - The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' (SRPT.O), opens new tab muscular disorder gene therapy Elevidys. The death occurred on June 7, the agency said.
Reuters
2 days ago
- Reuters
Atai and Recognify's schizophrenia drug fails to meet main goal in trial
July 25 (Reuters) - Atai Life Sciences ( opens new tab and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with schizophrenia-linked cognitive impairment. U.S.-listed shares of atai dropped about 17% in extended trading. The trial enrolled 242 patients with cognitive impairment associated with schizophrenia (CIAS), which affects memory, attention and decision-making in people with the mental illness. Recognify said patients taking the drug, inidascamine, showed some improvement in cognitive tests compared with a placebo, but the results were not statistically significant. Despite the drug missing the main goal, Recognify said patients on inidascamine showed consistent signs of improvement in areas such as processing speed and verbal learning, with positive trends on a test assessing real-world cognitive abilities. The drug was well-tolerated, with no signs of sedation, weight gain, or movement-related side effects, which are common with existing schizophrenia treatments. CIAS remains one of the most challenging and underserved areas in mental health, with no FDA-approved treatments. Atai and Recognify's setback adds to a string of failures in CIAS drug development, including last year's decision by Neurocrine Biosciences (NBIX.O), opens new tab to halt its own CIAS drug program after disappointing results. Cognitive deficits affect about 80% of people with schizophrenia, a condition that impacts roughly 24 million individuals globally, according to the World Health Organization. Standard treatment for schizophrenia typically involves antipsychotic medications that help manage hallucinations and delusions, but often do not address cognitive symptoms. Recognify, which is majority-owned by Berlin-based Atai, said it will continue to analyze full trial results and present further data at upcoming scientific meetings. Atai said it intends to focus resources on its own pipeline of psychedelic-based therapies for mood-affecting disorders, while continuing to support Recognify's efforts.
